Araştırma Makalesi
BibTex RIS Kaynak Göster
Yıl 2023, Cilt: 45 Sayı: 3, 28 - 35, 30.09.2023
https://doi.org/10.7197/cmj.1338902

Öz

Destekleyen Kurum

yok

Kaynakça

  • 1. Kumar A, Gangwar R, Ahmad Zargar A, Kumar R, Sharma A. Prevalence of diabetes in India: A review of IDF Diabetes Atlas 10th edition. Current Diabetes Reviews. 2023 Apr. DOI: 10.2174/1573399819666230413094200. PMID: 37069712.
  • 2. T.C. Sağlık Bakanlığı. Türkiye Diyabet Önleme ve Kontrol Programı Eylem Planı (2011-2014). Ankara: Anıl Matbaası, 2011
  • 3. International Diabetes Federation (IDF 2021). Diabetes Atlas) 9th ed. Erişim Tarihi:10.07.202. https://idf.org/e-library/ epidemiology-research/diabetes-atlas/159-idfdiabetes-atlas-ninth-edition-2021.htm
  • 4. Türkiye endokrinoloji ve metabolizma derneği (TEMD) diabetes mellitus ve komplikasyonlarının tanı, tedavi ve izlem kılavuzu-2022. Erişim Tarihi: 10.07.2023 http://temd.org.tr/admin/uploads/tbl_kilavuz/20200625154506-2020tbl_ kilavuz86bf012d90.pdf7syf 15.
  • 5. Satman, I., Omer, B., Tutuncu, Y., Kalaca, S., Gedik, S., & Dinccag N, et al.(2013). Twelveyear trends in the prevalence and risk factors of diabetes and prediabetes in Turkish adults. Eur J Epidemiol. 28 (2): 169–180. 6. Finnish Diabetes Association, Programme for the Prevention of Type 2 Diabetes in Finland 2003.2010.http://www.diabetes.fi/files/1108/Programme_for_the_Prevention_of_Type_2_Diabetes_in_Finland_2003-2010.pdf. Erişim tarihi: 15.10.2014.
  • 7. Lindström J, Tuomilehto J. A practical tool to predict type 2 diabetes risk. Diabetes Care 2003;26(3):725-31
  • 8. Kulak E, Berber B, Temel H, ve ark. Aile hekimliğine başvuran bireylerde tip 2 diyabet risk düzeyinin belirlenmesi. Türk Aile Hek Derg 2019; 23 (1): 20-30
  • 9. Çevik AB, Karaaslan MM, Koçan S, et al. Prevalence and screening for risk factors of type 2 diabetes in Rize, Nourtheast Turkey: findings from a population-based study. Prim Care Diabetes 2016;10(1):10-8.
  • 10. Kutlu R, Sayın S, Koçak A. Tanı Almamış Tip 2 Diyabet İçin Bir Tarama Metodu Olarak Fin Diyabet Risk Anketi (FINDRISK) Uygulanabilir mi? Konuralp Tıp Dergisi 2016;8(3):158-66.
  • 11. Cosansu G, Celik S, Özcan S, Olgun N, Yıldırım N, Demir HG. Determining type 2 diabetes risk factors for the adults: A community based study from Turkey. Prim Care Diabetes 2018;12(5):409-15.
  • 12. Zhang L, Zhang Z, Zhang Y, Hu G, Chen L. Evaluation of Finnish Diabetes Risk Score in screening undiagnosed diabetes and prediabetes among U.S. adults by gender and race: NHANES 1999- 2010. PLoS One 2014;9(5):e97865.
  • 13. Awad A, Alsaleh FM. 10-year risk estimation for type 2 diabetes mellitus and coronary heart disease in Kuwait: a cross-sectional population-based study. PLoS One 2015;10(1):e0116742.
  • 14. Makrilakis K, Liatis S, Grammatikou S, et al. Validation of the Finnish diabetes risk score (FINDRISC) questionnaire for screening for undiagnosed type 2 diabetes, dysglycaemia and the metabolic syndrome in Greece. Diabetes Metab 2011;37(2):144
  • 15. Janghorbani M, Adineh H, Amini M. Finnish Diabetes Risk Score to predict type 2 diabetes in the Isfahan diabetes prevention study. Diabetes Res Clin Pract.2013;102(3):202-9.
  • 16. Väätäinen S, Cederberg H, Roine R, et al. Does Future Diabetes Risk Impair Current Quality of Life? A Cross-Sectional Study of Health-Related Quality of Life in Relation to the Finnish Diabetes Risk Score (FINDRISC). PLoSOne.2016;11(2):e0147898.
  • 17. Cevik Akyil R, Miloglu O, Olgun N et al.A comparison of three different diabetes screening methods among dental patientsin Turkey. Pak J Med Sci.2014;30(1):65-9.
  • 18. Önder MR, ÖzerkanF. Diyabet ve Hipertansiyon. Türkiye KlinikleriJ Cardiol 2000;13(5):401-3
  • 19. Tankova T, Chakarova N, Atanassova I et al. Evaluation of the Finnish Diabetes Risk Score as a screening tool for impaired fasting glucose, impaired glucosetolerance and undetected diabetes. Diabetes Res Clin Pract. 2011;92(1):46-52.
  • 20. Costa B, Barrio F, Piñol JL, et al. Shifting from glucose diagnosis to the new HbA1c diagnosis reduces the capability ofthe Finnish Diabetes Risk Score (FINDRISC) to screen for glucose abnormalities with in a real life primary healthcare preventive strategy. BMC Med.2013;11:45
  • 21. Saaristo T, Peltonen M, Lindström J, et al. Cross-sectional evaluation of the Finnish Diabetes Risk Score: a tool to identify undetected type 2 diabetes, abnormal glucose tolerance and metabolic syndrome. Diab Vasc Dis Res 2005;2:67-72.

TYPE 2 DIABETES MELLITUS SCREENING: THE SAMPLE OF SİVAS

Yıl 2023, Cilt: 45 Sayı: 3, 28 - 35, 30.09.2023
https://doi.org/10.7197/cmj.1338902

Öz

ABSTRACT
Objective: The aim of the study is to screen for Type 2 Diabetes Mellitus (DM), to determine the risk of DM and to evaluate the factors affecting it.
Method: It is a descriptive study. The population of the research consisted of people over the age of 18 living in Sivas who were not diagnosed with diabetes. The sample of the research consisted of individuals over the age of 18 who did not have diabetes and participated in the event, which was organized as part of the 14 November 2022 “World Diabetes Day” event, which continued between 08.00-17.00. In order to reach the universe, a stand was set up in the city center in the square where the people are concentrated. Capillary blood glucose measurement, a questionnaire including height, weight, demographic characteristics and Finnish Diabetes Risk Questionnaire (FINDRISK) were applied to the patients. FINDRISK consists of 8 questions. It determines an individual's risk of developing diabetes in the next ten years. Results are shown as frequencies, mean±standard deviation. Pearson correlation analysis, Student-T test and One way ANOVA test were applied. P<0.05 was considered significant at the 95% confidence interval.
Results: 78.2% (n=560) of 716 participants were male and 21.8% (n=156) were female. 74.2%(n=531) of them were married. 39.5% (n=283) of them were primary school graduates. 30.2%(n=216) of them were working in any job. 30.9% (n=221) were smokers. 42.5% (n=304) had a chronic disease other than DM. Age groups; 25.8%(n=185) are under 45 years old, 17.7%(n=127) are 45-54 years old, 28.9%(n=207) are 55-64 years old, 27.5%(n=n= 197) of them were over 64 years old. The mean body mass index (BMI) of 684 people who accepted the height-weight measurement was 27.5±4.5. Capillary blood glucose mean of the participants was 130.9±57.0(min:51-max:494). The mean FINDRISK score was 11.1 ± 5.68(min:0-max:26). Participants' FINDRISK scores; 20.9%(143) were found to be high and 6.7%(46) were found to be very high. A weakly significant positive correlation was found between FINDRISK score and capillary blood glucose levels (p<0.001; r=0.244). A significant difference was found between the diabetes risk status of the participants and their marital status, education status, employment status, and presence of chronic disease (respectively; p<0.001; 0.004; 0.001; <0.001). The rate of diabetes was higher in married people than in single people, those who did not work than those who worked, and those who had additional chronic diseases than those without.
Conclusion: FINDRISK scores were found to be higher than different studies in the literature in the study conducted with population screening. Early identification of groups at high risk of diabetes will reduce the disease and burden of diabetes. At this stage, it will be advantageous to use easy-to-apply and inexpensive scanning methods such as FINDRISK.

Kaynakça

  • 1. Kumar A, Gangwar R, Ahmad Zargar A, Kumar R, Sharma A. Prevalence of diabetes in India: A review of IDF Diabetes Atlas 10th edition. Current Diabetes Reviews. 2023 Apr. DOI: 10.2174/1573399819666230413094200. PMID: 37069712.
  • 2. T.C. Sağlık Bakanlığı. Türkiye Diyabet Önleme ve Kontrol Programı Eylem Planı (2011-2014). Ankara: Anıl Matbaası, 2011
  • 3. International Diabetes Federation (IDF 2021). Diabetes Atlas) 9th ed. Erişim Tarihi:10.07.202. https://idf.org/e-library/ epidemiology-research/diabetes-atlas/159-idfdiabetes-atlas-ninth-edition-2021.htm
  • 4. Türkiye endokrinoloji ve metabolizma derneği (TEMD) diabetes mellitus ve komplikasyonlarının tanı, tedavi ve izlem kılavuzu-2022. Erişim Tarihi: 10.07.2023 http://temd.org.tr/admin/uploads/tbl_kilavuz/20200625154506-2020tbl_ kilavuz86bf012d90.pdf7syf 15.
  • 5. Satman, I., Omer, B., Tutuncu, Y., Kalaca, S., Gedik, S., & Dinccag N, et al.(2013). Twelveyear trends in the prevalence and risk factors of diabetes and prediabetes in Turkish adults. Eur J Epidemiol. 28 (2): 169–180. 6. Finnish Diabetes Association, Programme for the Prevention of Type 2 Diabetes in Finland 2003.2010.http://www.diabetes.fi/files/1108/Programme_for_the_Prevention_of_Type_2_Diabetes_in_Finland_2003-2010.pdf. Erişim tarihi: 15.10.2014.
  • 7. Lindström J, Tuomilehto J. A practical tool to predict type 2 diabetes risk. Diabetes Care 2003;26(3):725-31
  • 8. Kulak E, Berber B, Temel H, ve ark. Aile hekimliğine başvuran bireylerde tip 2 diyabet risk düzeyinin belirlenmesi. Türk Aile Hek Derg 2019; 23 (1): 20-30
  • 9. Çevik AB, Karaaslan MM, Koçan S, et al. Prevalence and screening for risk factors of type 2 diabetes in Rize, Nourtheast Turkey: findings from a population-based study. Prim Care Diabetes 2016;10(1):10-8.
  • 10. Kutlu R, Sayın S, Koçak A. Tanı Almamış Tip 2 Diyabet İçin Bir Tarama Metodu Olarak Fin Diyabet Risk Anketi (FINDRISK) Uygulanabilir mi? Konuralp Tıp Dergisi 2016;8(3):158-66.
  • 11. Cosansu G, Celik S, Özcan S, Olgun N, Yıldırım N, Demir HG. Determining type 2 diabetes risk factors for the adults: A community based study from Turkey. Prim Care Diabetes 2018;12(5):409-15.
  • 12. Zhang L, Zhang Z, Zhang Y, Hu G, Chen L. Evaluation of Finnish Diabetes Risk Score in screening undiagnosed diabetes and prediabetes among U.S. adults by gender and race: NHANES 1999- 2010. PLoS One 2014;9(5):e97865.
  • 13. Awad A, Alsaleh FM. 10-year risk estimation for type 2 diabetes mellitus and coronary heart disease in Kuwait: a cross-sectional population-based study. PLoS One 2015;10(1):e0116742.
  • 14. Makrilakis K, Liatis S, Grammatikou S, et al. Validation of the Finnish diabetes risk score (FINDRISC) questionnaire for screening for undiagnosed type 2 diabetes, dysglycaemia and the metabolic syndrome in Greece. Diabetes Metab 2011;37(2):144
  • 15. Janghorbani M, Adineh H, Amini M. Finnish Diabetes Risk Score to predict type 2 diabetes in the Isfahan diabetes prevention study. Diabetes Res Clin Pract.2013;102(3):202-9.
  • 16. Väätäinen S, Cederberg H, Roine R, et al. Does Future Diabetes Risk Impair Current Quality of Life? A Cross-Sectional Study of Health-Related Quality of Life in Relation to the Finnish Diabetes Risk Score (FINDRISC). PLoSOne.2016;11(2):e0147898.
  • 17. Cevik Akyil R, Miloglu O, Olgun N et al.A comparison of three different diabetes screening methods among dental patientsin Turkey. Pak J Med Sci.2014;30(1):65-9.
  • 18. Önder MR, ÖzerkanF. Diyabet ve Hipertansiyon. Türkiye KlinikleriJ Cardiol 2000;13(5):401-3
  • 19. Tankova T, Chakarova N, Atanassova I et al. Evaluation of the Finnish Diabetes Risk Score as a screening tool for impaired fasting glucose, impaired glucosetolerance and undetected diabetes. Diabetes Res Clin Pract. 2011;92(1):46-52.
  • 20. Costa B, Barrio F, Piñol JL, et al. Shifting from glucose diagnosis to the new HbA1c diagnosis reduces the capability ofthe Finnish Diabetes Risk Score (FINDRISC) to screen for glucose abnormalities with in a real life primary healthcare preventive strategy. BMC Med.2013;11:45
  • 21. Saaristo T, Peltonen M, Lindström J, et al. Cross-sectional evaluation of the Finnish Diabetes Risk Score: a tool to identify undetected type 2 diabetes, abnormal glucose tolerance and metabolic syndrome. Diab Vasc Dis Res 2005;2:67-72.
Toplam 20 adet kaynakça vardır.

Ayrıntılar

Birincil Dil İngilizce
Konular Aile Hekimliği, Birinci Basamak Sağlık Hizmetleri
Bölüm Temel Tıp Bilimleri Araştırma Yazıları
Yazarlar

Seher Karahan 0000-0002-4066-2928

Yayımlanma Tarihi 30 Eylül 2023
Kabul Tarihi 11 Eylül 2023
Yayımlandığı Sayı Yıl 2023Cilt: 45 Sayı: 3

Kaynak Göster

AMA Karahan S. TYPE 2 DIABETES MELLITUS SCREENING: THE SAMPLE OF SİVAS. CMJ. Eylül 2023;45(3):28-35. doi:10.7197/cmj.1338902